Visugromab

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1].

Product Specifications

CAS Number

[2556646-63-8]

Product Name Alternative

CTL-002

UNSPSC

12352203

Target

PD-1/PD-L1; TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/visugromab.html

Purity

98.40

Solubility

10 mM in DMSO|H2O

Smiles

[Visugromab]

Molecular Weight

(144.56 kDa)

References & Citations

[1]Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC) : A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER) [J]. 2023.|[2]Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637 (8048) :1218-1227.